Immatics Past Earnings Performance
Past criteria checks 0/6
Immatics has been growing earnings at an average annual rate of 15.6%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 26.7% per year.
Key information
15.6%
Earnings growth rate
30.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 26.7% |
Return on equity | -14.6% |
Net Margin | -48.3% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues
Sep 21Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans
Jul 12Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now
May 03We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Sep 26We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Jun 12Immatics launches $110M stock offering
Oct 10Cancer immunotherapy biotech Immatics up 18% on 4x normal volume
Jul 19Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation
Jan 29Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher
Dec 16Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Apr 01What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?
Jan 18Immatics reports Q3 results
Dec 02Immatics (IMTX) Investor Presentation - Slideshow
Nov 13Revenue & Expenses Breakdown
How Immatics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 116 | -56 | 43 | 0 |
30 Jun 24 | 71 | -74 | 41 | -2 |
31 Mar 24 | 74 | -80 | 40 | 0 |
31 Dec 23 | 54 | -97 | 38 | 0 |
30 Sep 23 | 76 | -84 | 38 | 0 |
30 Jun 23 | 85 | -79 | 37 | 7 |
31 Mar 23 | 80 | -68 | 36 | 0 |
31 Dec 22 | 173 | 38 | 36 | 0 |
30 Sep 22 | 151 | 34 | 35 | 0 |
30 Jun 22 | 142 | 28 | 35 | 0 |
31 Mar 22 | 130 | 15 | 35 | 0 |
31 Dec 21 | 35 | -93 | 34 | 0 |
30 Sep 21 | 28 | -95 | 34 | 0 |
30 Jun 21 | 30 | -231 | 35 | 0 |
31 Mar 21 | 32 | -226 | 36 | 0 |
31 Dec 20 | 31 | -211 | 34 | 0 |
30 Sep 20 | 26 | -208 | 30 | 0 |
30 Jun 20 | 23 | -49 | 24 | 0 |
31 Mar 20 | 22 | -34 | 16 | 0 |
31 Dec 19 | 18 | -32 | 12 | 0 |
31 Dec 18 | 4 | -31 | 8 | 0 |
Quality Earnings: IMTX is currently unprofitable.
Growing Profit Margin: IMTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMTX is unprofitable, but has reduced losses over the past 5 years at a rate of 15.6% per year.
Accelerating Growth: Unable to compare IMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: IMTX has a negative Return on Equity (-14.59%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/10 23:41 |
End of Day Share Price | 2025/01/10 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immatics N.V. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Alec Stranahan | BofA Global Research |
Eric Schmidt | Cantor Fitzgerald & Co. |
Yevgeniya Livshits | Chardan Capital Markets, LLC |